{"id":"NCT03930732","sponsor":"Sanofi","briefTitle":"Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe COPD With Type 2 Inflammation","officialTitle":"A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-04-15","primaryCompletion":"2023-02-08","completion":"2023-05-02","firstPosted":"2019-04-29","resultsPosted":"2024-02-28","lastUpdate":"2024-02-28"},"enrollment":939,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Obstructive Pulmonary Disease"],"interventions":[{"type":"DRUG","name":"Dupilumab SAR231893","otherNames":["Dupixent"]},{"type":"DRUG","name":"Inhaled Corticosteroid","otherNames":[]},{"type":"DRUG","name":"Inhaled Long-Acting Beta Agonist","otherNames":[]},{"type":"DRUG","name":"Inhaled Long-Acting Muscarinic Antagonist","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Dupilumab","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"Primary Objective:\n\nTo evaluate the efficacy of dupilumab administered every 2 weeks in patients with moderate-or severe Chronic Obstructive Pulmonary Disease (COPD) as measured by\n\n* Annualized rate of acute moderate and severe COPD exacerbation (AECOPD)\n\nSecondary Objectives:\n\nTo evaluate the effect of dupilumab administered every 2 weeks on\n\n* Pre-bronchodilator forced expiratory volume in 1 second (FEV1) over 12 weeks compared to placebo\n* Health related quality of life, assessed by the change from baseline to Week 52 in the St. George's Respiratory Questionnaire (SGRQ)\n* Pre-bronchodilator FEV1 over 52 weeks compared to placebo\n* Lung function assessments\n* Moderate and severe COPD exacerbations\n* To evaluate safety and tolerability\n* To evaluate dupilumab systemic exposure and incidence of anti-drug antibodies (ADA)","primaryOutcome":{"measure":"Annualized Rate of Moderate or Severe Chronic Obstructive Pulmonary Disease (COPD) Exacerbations Over the 52-Week Treatment Period","timeFrame":"Baseline (Day 1) to Week 52","effectByArm":[{"arm":"Placebo","deltaMin":1.01,"sd":null},{"arm":"Dupilumab 300 mg q2w","deltaMin":0.776,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0005"}]},"eligibility":{"minAge":"40 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":10},"locations":{"siteCount":275,"countries":["United States","Argentina","Bulgaria","Canada","Chile","China","Czechia","Denmark","Finland","Germany","Hungary","Israel","Italy","Japan","Mexico","Poland","Romania","Russia","Slovakia","South Korea","Spain","Sweden","Turkey (TÃ¼rkiye)","Ukraine"]},"refs":{"pmids":["40651490","40024335","39894389","39481660","37272521"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":74,"n":470},"commonTop":["Nasopharyngitis","Upper Respiratory Tract Infection","Headache","Accidental Overdose","Hypertension"]}}